Mersana Therapeutics Inc (NAS:MRSN)
$ 2.48 -0.07 (-2.75%) Market Cap: 315.01 Mil Enterprise Value: 188.87 Mil PE Ratio: 0 PB Ratio: 296.11 GF Score: 41/100

Mersana Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 16, 2020 / 05:00PM GMT
Release Date Price: $7.61 (+23.54%)
Yuko Oku
JP Morgan Chase & Co, Research Division - Analyst

Hi. I'm Yuko Oku, one of the associates on the biotech team. It's a pleasure to introduce Mersana to the JPMorgan Healthcare Conference today. Just a quick housekeeping note, we'll be hosting a Q&A session right after the presentation in the Victorian Room. And with that, I'd like to turn it over to President and CEO, Anna Protopapas.

Anna Protopapas
Mersana Therapeutics, Inc. - President, CEO & Director

Thank you. Before I start, I just want to remind you that I will be making forward-looking statements. 2020 is a very important year for Mersana. It's a year rich in both milestones and data disclosures. Our lead asset, 1536, is a first-in-class molecule addressing important unmet medical needs in ovarian and lung adenocarcinoma. 1536 is in 2 proof-of-concept studies that are on track to complete in 2020 and then subsequently support registration-enabling studies, including fast-to-market opportunities in later-stage ovarian cancer patients.

Beyond 1536, we have a new IND and 2

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot